Full-Time

Senior Medical Director Clinical Development Neuroscience

Arvinas

Arvinas

201-500 employees

Clinical-stage biopharma developing PROTAC degraders

No salary listed

No H1B Sponsorship

Remote in USA + 1 more

More locations: New Haven, CT, USA

Hybrid

Remote within the United States with hybrid/onsite options in New Haven, Connecticut.

MD

Category
Medical, Clinical & Veterinary (1)

Get referred to Arvinas

See people who can refer or advise you

Requirements
  • A minimum of five years of biotech/pharma experience in neurological disease clinical drug development, with seven or more years strongly preferred.
  • Experience across multiple stages of clinical development, from Investigational New Drug application to New Drug Application or Biologics License Application.
  • Global clinical development experience is required, and global filing experience is preferred.
  • Technical (Medical and Scientific) experience evaluating targets or agents for in-licensing or internal development.
  • Experience supervising physicians and/or scientific staff in a management or team leader capacity is highly desirable.
  • Excellent interpersonal and public speaking skills are required for this high visibility position.
  • Demonstrated ability to work in a matrix environment with cross-functional teams.
  • Must be legally authorized to work in the United States without the need for employer sponsorship now or at any time in the future.
  • The duties of this role are generally conducted in a home office environment, with ability to use computer, engage in communications, problem solving, and collaboration.
  • A Doctor of Medicine degree or equivalent is required.
  • Formal training in Neurology and professional board certification are highly preferred.
Responsibilities
  • Partner with discovery and biology leadership and provide clinical input and guidance to develop the neuroscience corporate strategy.
  • Design Phase I/II/III research trials targeting neurologic diseases, requiring expertise and stewardship in the areas of central nervous system neurology.
  • Monitor the safety of patients enrolled in clinical studies.
  • Provide medical and scientific input in review of clinical data, patient medical safety data, and laboratory values, maintaining an ongoing assessment of the safety profile and efficacy data, as appropriate.
  • Work closely with all functions of the organization and external partners to manage trial execution and investigators’ engagement.
  • Collaborate in developing global regulatory plans and play a key role in regulatory meetings in partnership with regulatory affairs.
  • Identify, develop, and maintain relationships with external experts to better understand the candidate drug’s effects and gain strategic insights to strengthen the program.
  • Provide clinical assessments of potential in-licensing assets, identifying novel therapeutics opportunities as well as critical study design and execution challenges.
  • Lead the interpretation and summary of clinical trial data, including the preparation of study reports, integrated summaries, and clinical portions of package inserts and other product labeling.
  • Provide input on and review of various reports, applications, and publications.
  • Ensure consistent practices with the highest ethical standards in compliance with internal SOPs, local regulations, and laws.
  • Participate in the selection of clinical investigators.
  • Provide guidance to study investigators.
  • Provide medical support to Clinical Operations in the oversight of contract research organizations.
  • Contribute to the overall strategy for drug development.
  • Collaborate on the preparation and submission of IND, Clinical Trial Application, and New Drug Application documents, and safety reports.
  • Support the clinical aspects of interactions with regulatory agencies worldwide.
  • Participate in the planning, writing, and review of Clinical Study Reports, regulatory updates, and submissions.
  • Analyze and interpret study data for abstracts or publication as required.
  • Assist in the evaluation of scientific opportunities by contributing to due diligence activities, including critical assessment of clinical and translational data.
  • Provide medical expertise to support corporate partnering and business development efforts, including active participation in partnership committees and cross-functional task groups.
  • Collaborate with senior leadership and cross-functional teams to inform overall company strategy and contribute to the identification, evaluation, and in-licensing of new programs.
  • Work with the financial group as needed to assist with the production of budgets and timelines for the clinical development team.
  • Ensure that medical activities in clinical trials are conducted in compliance with Good Clinical Practice standards.
Desired Qualifications
  • Formal Neurology training and professional board certification highly preferred.
  • Global filing experience preferred.
  • Experience in supervising physicians and/or scientists in a management or team leader capacity is desirable.

Arvinas develops PROTAC-based protein degraders in clinical-stage biopharmaceutical programs aimed at diseases driven by harmful proteins, including cancer and neurodegenerative disorders. Its PROTAC platform works by linking a disease-causing protein to an E3 ligase, tagging the target for degradation by the cell’s proteasome rather than merely inhibiting it. Revenue comes from partnerships, collaborations, and licensing deals with other pharma companies, as well as the potential commercialization of its drug candidates. The company’s goal is to improve patient outcomes by delivering targeted, mechanism-based therapies and advancing its drug candidates through discovery, development, and potential commercialization.

Company Size

201-500

Company Stage

IPO

Headquarters

New Haven, Connecticut

Founded

2013

Get referred to Arvinas

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $249.7 million from VEPPANU licensing and Pfizer deferred revenue.
  • Cash and marketable securities totaled $567.9 million on June 30, 2026, funding 2028.
  • Arvinas expects ARV-393, ARV-027, and ARV-102 data catalysts across 2026-2027.

What critics are saying

  • ARV-102 remains on U.S. clinical hold pending toxicology, delaying neurology trials into 2027.
  • Randy Teel replaced John Houston in February 2026, signaling execution pressure after repeated restructurings.
  • If ARV-393 and ARV-027 disappoint, Arvinas becomes a single-partnered royalty story.

What makes Arvinas unique

  • First FDA-approved PROTAC VEPPANU validated Arvinas' degrader platform and boosted partner interest.
  • Deep pipeline spans oncology and neurology: ARV-393, ARV-027, ARV-102, ARV-806.
  • Rigel's 2026 launch and Pfizer collaboration prove pharma trusts Arvinas' chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Aug 11th, 2026
Arvinas shifts focus to Phase I programmes after first PROTAC degrader approval

Arvinas reported progress on several strategic initiatives during its second quarter 2026 earnings call. The company achieved three key milestones this year: securing the first FDA approval for a PROTAC degrader, VEPPANU; completing an out-licensing deal for VEPPANU with Rigel Pharmaceuticals; and deciding to advance its KRAS G12D programme, ARV-806, only through a partnership. President and Chief Executive Officer Randy Teel said the company is focusing on advancing transformational improvements for patients through continued innovation and disciplined execution. The strategic decisions have positioned Arvinas to concentrate fully on its Phase I clinical programmes in oncology and neurology. The company determined that ARV-806 requires investment inconsistent with its current capital allocation strategy, though it believes the programme has potential as a meaningful treatment option.

Yahoo Finance
Aug 4th, 2026
Arvinas secures first FDA approval for PROTAC degrader, shifts focus to oncology and neurology pipelines

Arvinas has achieved the first-ever FDA approval of a PROTAC degrader, VEPPANU, validating its protein degradation platform. The company has out-licensed VEPPANU to Rigel Pharmaceuticals for $249.7 million and shifted focus to Phase I oncology and neurology programmes. The company will only advance its KRAS G12D programme through a partnership. Initial Phase I data for ARV-393 (BCL6) is expected by year-end 2026, whilst proof-of-mechanism data for ARV-027 is anticipated in the first half of 2027. Arvinas established a $52.7 million liability to cover remaining VEPPANU development obligations. Non-GAAP R&D expenses decreased 14% year-over-year following 2025 cost-reduction programmes. The company maintains a cash runway extending into the second half of 2028. ARV-102 faces a technical clinical hold in the US pending additional toxicology data.

Yahoo Finance
Aug 4th, 2026
Arvinas shifts to early-stage pipeline after FDA approves first PROTAC degrader VEPPANU

Arvinas is redirecting resources to early-stage oncology and neurology programmes following FDA approval of VEPPANU, the first PROTAC degrader, which was licensed to Rigel Pharmaceuticals. The company's KRAS G12D programme, ARV-806, will only progress through a partner. Key clinical catalysts are expected for ARV-393 in lymphoma by year-end 2026, ARV-027 in spinal and bulbar muscular atrophy in the first half of 2027, and ARV-102 trials in neurodegenerative disease beginning in 2027. Arvinas reported $249.7 million in second-quarter revenue, including licence and milestone payments tied to VEPPANU. Cash and marketable securities totalled $567.9 million at 30 June, with management maintaining a cash runway into the second half of 2028.

Yahoo Finance
Aug 4th, 2026
Arvinas secures first-ever PROTAC regulatory approval, out-licenses VEPPANU to Rigel Pharmaceuticals

Arvinas secured the first regulatory approval for a PROTAC protein degrader with VEPPANU and licensed it to Rigel Pharmaceuticals. The treatment is approved for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer following at least one line of endocrine therapy. The company expects to share clinical data from three Phase 1 programmes — ARV-393, ARV-102, and ARV-027 — over the next 12 months. Arvinas is initiating a Phase 1 trial for ARV-6723, an HPK1 degrader showing single-agent activity in preclinical models. The National Comprehensive Cancer Network added VEPPANU to its clinical practice guidelines for breast cancer as a Category 2A treatment option.

Associated Press
Aug 4th, 2026
Arvinas secures first-ever PROTAC approval, licenses VEPPANU to Rigel Pharmaceuticals

Arvinas reported second quarter 2026 financial results, highlighting VEPPANU's approval as the first-ever PROTAC protein degrader therapy and its subsequent out-licensing to Rigel Pharmaceuticals. The company plans to share clinical data from three Phase 1 programmes over the next 12 months. As of 30 June 2026, Arvinas held $567.9 million in cash, cash equivalents, and marketable securities, down from $685.4 million at year-end 2025. The company expects these funds to sustain operations into the second half of 2028. Second quarter revenue reached $249.7 million, compared with $22.4 million in the same period last year. The increase was primarily driven by recognition of deferred revenue from its Pfizer collaboration and $62.5 million from the Rigel licence agreement. Research and development expenses decreased to $52.6 million from $68.6 million year-over-year.